BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1164@pharmaconomics
DTSTAMP:20260707T020112Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:ARGX Phase 2 — VYVGART (estimated date)
DESCRIPTION:Phase 2 trial results for VYVGART in autoimmune inflammatory myopathies (AIM or myositis) are due ~ Jun 30\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1697862/000110465926002867/tm262664d1_ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/1164
URL:https://pharmaconomics.com/e/1164
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ARGX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR